Business Description
NewAmsterdam Pharma Co NV
ISIN : NL00150012L7
Total Employee Number:
100Description
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. The Company has one reportable segment, which comprises the discovery, development, and commercialization of transformative therapies for cardio-metabolic diseases.
Financial Strength
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 7729.93 | |||||
Equity-to-Asset | 0.9 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | 25.23 | |||||
Beneish M-Score | -4.37 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -67.3 | |||||
3-Year EBITDA Growth Rate | -17.4 | |||||
3-Year EPS without NRI Growth Rate | -39.1 | |||||
3-Year Book Growth Rate | 4.2 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 50.98 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 185.35 |
Momentum Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 42.83 | |||||
9-Day RSI | 37.52 | |||||
14-Day RSI | 38.63 | |||||
3-1 Month Momentum % | 6.14 | |||||
6-1 Month Momentum % | 7.84 | |||||
12-1 Month Momentum % | 61.11 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 9.03 | |||||
Quick Ratio | 9.03 | |||||
Cash Ratio | 8.69 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -11.9 | |||||
Shareholder Yield % | 0.01 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Operating Margin % | -3432.2 | |||||
Net Margin % | -3644.21 | |||||
EBITDA Margin % | -3428.77 | |||||
FCF Margin % | -2018.28 | |||||
OCF Margin % | -2014.63 | |||||
ROE % | -37.21 | |||||
ROA % | -34.07 | |||||
ROIC % | -211.33 | |||||
3-Year ROIIC % | -154.54 | |||||
ROC (Joel Greenblatt) % | -46114.53 | |||||
ROCE % | -35.05 | |||||
Moat Score | 6 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 482.07 | |||||
PB Ratio | 5.21 | |||||
Price-to-Tangible-Book | 5.22 | |||||
EV-to-EBIT | -11.08 | |||||
EV-to-Forward-EBIT | -11.28 | |||||
EV-to-EBITDA | -11.09 | |||||
EV-to-Forward-EBITDA | -11.28 | |||||
EV-to-Revenue | 380.35 | |||||
EV-to-Forward-Revenue | 66.1 | |||||
EV-to-FCF | -18.85 | |||||
Price-to-GF-Value | 2.68 | |||||
| Price-to-Net-Current-Asset-Value | 5.61 | |||||
| Price-to-Net-Cash | 5.86 | |||||
Earnings Yield (Greenblatt) % | -9.03 | |||||
FCF Yield % | -4.3 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:NAMS
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
NewAmsterdam Pharma Co NV Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 7.121 | ||
| EPS (TTM) ($) | -2.16 | ||
| Beta | 0.7247 | ||
| 3-Year Sharpe Ratio | 0.64 | ||
| 3-Year Sortino Ratio | 1.66 | ||
| Volatility % | 56.39 | ||
| 14-Day RSI | 38.63 | ||
| 14-Day ATR ($) | 1.605551 | ||
| 20-Day SMA ($) | 29.7815 | ||
| 12-1 Month Momentum % | 61.11 | ||
| 52-Week Range ($) | 23.05 - 42.205 | ||
| Shares Outstanding (Mil) | 119.54 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
NewAmsterdam Pharma Co NV Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
NewAmsterdam Pharma Co NV Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-05 | In 89 days | ||
| Second quarter earnings results for 2026 | 2026-08-05 | 27.55 (-0.97%) | ||
| Goldman Sachs 47th Annual Global Healthcare Conference | 2026-06-09 14:40 | 30.95 (-2.86%) | ||
| Guidance call for 2026 | 2026-06-03 10:30 | 31.71 (+0.35%) | ||
| General meeting for 2026 | 2026-06-02 17:00 | 31.79 (-4.02%) | ||
| Guidance call for 2026 | 2026-05-20 14:05 | 33.72 (-0.50%) | ||
| Guidance call for 2026 | 2026-05-12 17:15 | 39.59 (+4.89%) | ||
| First quarter earnings results for 2026 | 2026-05-07 | 30.99 (+3.20%) | ||
| 25th Annual Needham Virtual Healthcare Conference | 2026-04-13 11:45 | 34.76 (-1.92%) | ||
| Guidance call for 2026 | 2026-03-09 08:40 | 29.86 (+1.39%) |
Show
Entries
NewAmsterdam Pharma Co NV Frequently Asked Questions
What is NewAmsterdam Pharma Co NV(NAMS)'s stock price today?
The current price of NAMS is $27.96. The 52 week high of NAMS is $42.21 and 52 week low is $23.05.
When is next earnings date of NewAmsterdam Pharma Co NV(NAMS)?
The next earnings date of NewAmsterdam Pharma Co NV(NAMS) is 2026-11-05 Est..
Does NewAmsterdam Pharma Co NV(NAMS) pay dividends? If so, how much?
NewAmsterdam Pharma Co NV(NAMS) does not pay dividend.
Guru Commentaries on NAS:NAMS
No articles.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on NewAmsterdam Pharma Co NV
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers